Latest treatment progress of heart failure

doi:10.3969/j.issn.1674-490X.2025.06.002

Abstract

Abstract: Heart failure is a syndrome characterized by impaired ventricular filling and/or ejection function, often caused by various cardiac structures or functional impairments. The cardiac output cannot meet the metabolic needs of body tissues, resulting in pulmonary and/or systemic congestion, as well as inadequate blood perfusion to organs and tissues. Heart failure affects approximately 64 million people worldwide. In recent years, significant progress has been made in the treatment of heart failure in various fields such as internal and external medicine, from the “Golden Triangle” to the “New Four Links” and then to the “Five Golden Flowers”. From “heart transplantation” to “cardiac resynchronization therapy” and then to “left ventricular assist device”. By referring to existing clinical research and practice, we mainly summarize effective measures for the prevention and treatment of heart failure(mainly chronic heart failure), providing reference for clinical doctors.

Key words: heart failure, treatment, new

CLC Number:

ZHAO Yang, CHEN Siji, LIN Shuwu. Latest treatment progress of heart failure[J]. Journal of Hebei Medical College for Continuing Education, 2025, 42(6): 15-25.

References

[1] 王喆.《中国心力衰竭诊断和治疗指南2014》解读[J].中国临床医生杂志, 2016, 44(5): 14-16. DOI: 10.3969/j.issn.2095-8552.2016.05.006.
[2] MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. DOI: 10.1093/eurheartj/ehab368.
[3] SHAFIQ A, HAMEED I, BIEGUS J, et al. Empagliflozin in the treatment of heart failure[J]. Future Cardiol, 2024, 20(5/6): 251-261. DOI: 10.1080/14796678.2024.2360818.
[4] NILSSON C N, ERSBØLL M K, GUSTAFSSON F. Haemodynamic effects of sodium-glucose cotransporter 2 inhibitor treatment in chronic heart failure patients[J]. Card Fail Rev, 2024, 10: e09. DOI: 10.15420/cfr.2023.25.
[5] 赵代鑫,胡晓军,晏凯利,等.基于网络Meta分析对比不同钠-葡萄糖协同转运蛋白2抑制剂对慢性心力衰竭患者预后的影响[J].医学研究与教育,2024,41(5):1-10.DOI: 10.3969/j.issn.1674490X.2024.05.001.
[6] 田庄,张抒扬.《中国心力衰竭诊断和治疗指南2024》要点解读[J].协和医学杂志, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292.
[7] VADUGANATHAN M, DOCHERTY K F, CLAGGETT B L, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensivemeta-analysis of five randomised controlled trials[J]. Lancet, 2022, 400(10354): 757-767. DOI: 10.1016/S0140-6736(22)01429-5.
[8] JHUND P S, KONDO T, BUTT J H, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysisof DAPA-HF and DELIVER[J]. Nat Med, 2022, 28(9): 1956-1964. DOI: 10.1038/s41591-022-01971-4.
[9] DE BOER R A, HULOT J S, TOCCHETTI C G, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association(HFA)of the European Society of Cardiology(ESC)[J]. Eur J Heart Fail, 2020, 22(12): 2272-2289. DOI: 10.1002/ejhf.2029.
[10] KADOWAKI T, ISENDAHL J, KHALID U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population(STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2022, 10(3): 193-206. DOI: 10.1016/S2213-8587(22)00008-0.
[11] WADDEN T A, BAILEY T S, BILLINGS L K, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial[J]. Jama, 2021, 325(14): 1403. DOI: 10.1001/jama.2021.1831.
[12] SCHEEN A J. GLP-1 receptor agonists and heart failure in diabetes[J]. Diabetes Metab, 2017, 43: 2S13-2S19. DOI: 10.1016/S1262-3636(17)30068-X.
[13] 王增武.《中国高血压防治指南(2024年修订版)》更新要点解读[J].中国心血管杂志, 2024, 29(5): 391-395. DOI: 10.3969/j.issn.1007-5410.2024.05.001.
[14] SENNI M, MCMURRAY J J V, WACHTER R, et al. Initiating sacubitril/valsartan(LCZ696)in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J]. Eur J Heart Fail, 2016, 18(9): 1193-1202. DOI: 10.1002/ejhf.548.
[15] SOLOMON S D, MCMURRAY J J V, ANAND I S, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17): 1609-1620.DOI: 10.1056/nejmoa1908655.
[16] MCMURRAY J J V, JACKSON A M, LAM C S P, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF[J]. Circulation, 2020, 141(5): 338-351.DOI: 10.1161/CIRCULATIONAHA.119.044491.
[17] 李锦,蔡琳.《2021 ESC急慢性心力衰竭诊断和治疗指南(2023重点更新)》要点解读[J].心血管病学进展, 2024, 45(1): 74-78. DOI: 10.16806/j.cnki.issn.1004-3934.2024.01.019.
[18] KINTSCHER U, EDELMANN F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2023, 22(1): 162. DOI: 10.1186/s12933-023-01899-0.
[19] 唐婷婷,廖玉华. 《2023 ESC急性和慢性心力衰竭诊断和治疗指南》更新要点解读[J].临床心血管病杂志, 2023, 39(10): 749-752. DOI: 10.13201/j.issn.1001-1439.2023.10.003.
[20] BAUERSACHS J, LÓPEZ-ANDRÉS N. Mineralocorticoid receptor in cardiovascular diseases-Clinical trials and mechanistic insights[J]. Br J Pharmacol, 2022, 179(13): 3119-3134. DOI: 10.1111/bph.15708.
[21] 王华,李莹莹. 2022年AHA/ACC/HFSA心力衰竭管理指南解读:从新指南看心衰分类和诊断评估[J].中国心血管病研究, 2022, 20(6): 481-486. DOI: 10.3969/j.issn.1672-5301.2022.06.001.
[22] WU L L, RODRIGUEZ M, EL HACHEM K, etal. Diuretic treatment in heart failure: a practical guide for clinicians[J]. J Clin Med, 2024, 13(15): 4470. DOI: 10.3390/jcm13154470.
[23] TEIXEIRA L, FELIX N, NAVALHA D D P, et al. Torsemide versus furosemide in the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials[J]. Arq Bras Cardiol, 2024, 121(6): e20230825. DOI: 10.36660/abc.20230825.
[24] HORIUCHI Y, WETTERSTEN N. Treatment strategies for diuretic resistance in patients with heart failure[J]. J Cardiol, 2025, 85(1): 1-7. DOI: 10.1016/j.jjcc.2024.06.005.
[25] 董蔚,任景怡,徐东杰.心力衰竭患者利尿剂抵抗诊断及管理中国专家共识[J].临床心血管病杂志,2024,40(4):257-267.DOI: 10.13201/j.issn.1001-1439.2024.04.002.
[26] TERPOS V, ROUMELIOTIS S, GEORGIANOS P I, et al. Diuretics or ultrafiltration in the treatment of acute decompensated heart failure: an updated systematic review and meta-analysis[J]. Ther Apher Dial, 2024, 28(1): 9-22. DOI: 10.1111/1744-9987.14037.
[27] YANCY C W, JESSUP M, BOZKURT B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America[J]. Circulation, 2017, 136(6): e137-e161. DOI: 10.1161/CIR.0000000000000509.
[28] ZHOU S J, LIU Y, HUANG X F, et al. Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future[J]. Front Cardiovasc Med, 2024, 11: 1337154. DOI: 10.3389/fcvm.2024.1337154.
[29] 朱美润,郎爽,邢卓,等.新活素联合左西孟旦治疗慢性心衰急性发作的临床效果观察[J].中国现代药物应用, 2022, 16(1): 17-19. DOI: 10.14164/j.cnki.cn11-5581/r.2022.01.005.
[30] 李文俊,武云,赵建全,等.利尿剂抵抗的研究进展[J]. 内蒙古医学杂志, 2021, 53(6): 697-700. DOI: 10.16096/J.cnki.nmgyxzz.2021.53.06.016.
[31] TEERLINK J R, DIAZ R, FELKER G M, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF[J]. JACC Heart Fail, 2020, 8(4): 329-340. DOI: 10.1016/j.jchf.2019.12.001.
[32] 胡大一,黄德嘉,袁祖贻,等.盐酸伊伐布雷定治疗中国慢性心力衰竭患者的有效性及安全性评价:伊伐布雷定与慢性心力衰竭预后研究中国亚组数据分析[J].中华高血压杂志, 2017, 25(10): 1000. DOI: 10.16439/j.cnki.1673-7245.2017.10.038.
[33] 孙卫卫,王冬颖,崔英凯,等.充血性心力衰竭气虚血瘀证治疗的研究进展[J].医学研究与教育, 2018,35(4): 24-28.DOI: 10.3969/j.issn.1674-490X.2018.04.005.
[34] SUN J, ZHANG K, XIONG W J, et al. Clinical effects of a standardized Chinese herbal remedy, Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis[J]. BMC Complement Altern Med, 2016, 16: 201. DOI: 10.1186/s12906-016-1174-1.
[35] PACKER M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism[J]. Nat Rev Cardiol, 2023, 20(7): 443-462. DOI: 10.1038/s41569-022-00824-4.
[36] 黄晓华,唐名扬,欧登科,等.心脏再同步化治疗在心力衰竭中的研究进展[J].心血管病学进展, 2022, 43(7): 645-648,656. DOI: 10.16806/j.cnki.issn.1004-3934.2022.07.015.
[37] CAZEAU S, LECLERCQ C, LAVERGNE T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay[J]. N Engl J Med, 2001, 344(12): 873-880. DOI: 10.1056/nejm200103223441202.
[38] EPSTEIN A E, DIMARCO J P, ELLENBOGEN K A, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices)developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2008, 51(21): e1-e62. DOI: 10.1016/j.jacc.2008.02.032.
[39] SLOTWINER D J, RAITT M H, DEL-CARPIO MUNOZ F, et al. Impact of physiologic pacing versus right ventricular pacing among patients with left ventricular ejection fraction greater than 35%: a systematic review for the 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society[J]. Circulation, 2019, 140(8): e483-e503. DOI: 10.1161/CIR.0000000000000629.
[40] CONNOLLY S J, HALLSTROM A P, CAPPATO R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID,CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg.Canadian Implantable Defibrillator Study[J]. Eur Heart J, 2000, 21(24): 2071-2078. DOI: 10.1053/euhj.2000.2476.
[41] BARDY G H, LEE K L, MARK D B, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J]. N Engl J Med, 2005, 352(3): 225-237. DOI: 10.1056/nejmoa043399.
[42] WIEGN P, CHAN R, JOST C, et al. Safety, performance, and efficacy of cardiac contractility modulation delivered by the 2-lead optimizer smart system: the FIX-HF-5C2 study[J]. Circ Heart Fail, 2020, 13(4): e006512. DOI: 10.1161/CIRCHEARTFAILURE.119.006512.
[43] THEOCHARI C A, MICHALOPOULOS G, OIKONOMOU E K, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis[J]. Ann Cardiothrac Surg, 2018, 7(1): 3-11. DOI: 10.21037/acs.2017.09.18.
[44] MEHRA M R, URIEL N, NAKA Y, et al. A fully magnetically levitated left ventricular assist device: final report[J]. N Engl J Med, 2019, 380(17): 1618-1627. DOI: 10.1056/NEJMoa1900486.
[45] LUND L H, KHUSH K K, CHERIKH W S, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time[J]. J Heart Lung Transplant, 2017, 36(10): 1037-1046. DOI: 10.1016/j.healun.2017.07.019.
[46] GOSEV I, KIERNAN M S, ECKMAN P, et al. Long-term survival in patients receiving a continuous-flow left ventricular assist device[J]. Ann Thorac Surg, 2018, 105(3): 696-701. DOI: 10.1016/j.athoracsur.2017.08.057.
[47] LAGGERBAUER B, ENGELHARDT S.microRNAs as therapeutic targets in cardiovascular disease[J]. J Clin Investig, 2022, 132(11): e159179. DOI: 10.1172/jci159179.
[48] PATEREK A, ZAŁSKA-KOCICKA M, SURZYKIEWICZ M, et al. Non-coding RNA therapeutics in the treatment of heart failure[J]. Eur Heart J Cardiovasc Pharmacother, 2024, 10(4): 353-360. DOI: 10.1093/ehjcvp/pvae027.
[49] MACKIEWICZ U, MACZEWSKI M, KLEMENSKA E, et al. Brief postinfarction calcineurin blockade affects left ventricular remodeling and Ca²⁺ handling in the rat[J]. J Mol Cell Cardiol, 2010, 48(6): 1307-1315. DOI: 10.1016/j.yjmcc.2009.12.016.
[50] BONAUER A, CARMONA G, IWASAKI M, et al.microRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice[J]. Science, 2009, 324(5935): 1710-1713. DOI: 10.1126/science.1174381.
[51] SAYED D, HE M Z, HONG C, et al.microRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand[J]. J Biol Chem, 2010, 285(26): 20281-20290. DOI: 10.1074/jbc.M110.109207.
[52] ZHOU L, WANG L J, LU L N, et al. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts[J]. PLoS One, 2012, 7(3): e33766. DOI: 10.1371/journal.pone.0033766.
[53] HAIDER H K, ASHRAF M. Bone marrow stem cell transplantation for cardiac repair[J]. Am J Physiol Heart Circ Physiol, 2005, 288(6): H2557-H2567. DOI: 10.1152/ajpheart.01215.2004.
[54] HARE J M, FISHMAN J E, GERSTENBLITH G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial[J]. JAMA, 2012, 308(22): 2369-2379. DOI: 10.1001/jama.2012.25321.
[55] QUYYUMI A A, WALLER E K, MURROW J, et al. CD34⁺ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent[J]. Am Heart J, 2011, 161(1): 98-105. DOI: 10.1016/j.ahj.2010.09.025.
[56] VON HAEHLING S, GREMMLER U, KRUMM M, et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP Registry[J]. Clin Res Cardiol, 2017, 106(6): 436-443. DOI: 10.1007/s00392-016-1073-y.
[57] GROENVELD H F, JANUZZI J L, DAMMAN K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2008, 52(10): 818-827. DOI: 10.1016/j.jacc.2008.04.061.
[58] ENNEZAT P V, MARÉCHAUX S, PIN?瘙塁ON C, et al. Anaemia to predict outcome in patients with acute coronary syndromes[J]. Arch Cardiovasc Dis, 2013, 106(6/7): 357-365. DOI: 10.1016/j.acvd.2013.04.004.
[59] MCCULLOUGH P A, BARNARD D, CLARE R, et al. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function[J]. Clin Cardiol, 2013, 36(10): 611-620. DOI: 10.1002/clc.22181.
[60] TKACZYSZYN M, FUDIM M, PONIKOWSKI P, et al. Pathophysiology and treatment opportunities of iron deficiency in heart failure: is there a need for further trials?[J]. Curr Heart Fail Rep, 2023, 20(4): 300-307. DOI: 10.1007/s11897-023-00611-3.
[61] BIANCHI V E, VON HAEHLING S. The treatment of chronic Anemia in heart failure: a global approach[J]. Clin Res Cardiol, 2024, 113(8): 1117-1136. DOI: 10.1007/s00392-023-02275-4.
[62] PERTICONE M, ZITO R, MICELI S, et al. Immunity, inflammation and heart failure: their role on cardiac function and iron status[J]. Front Immunol, 2019, 10: 2315. DOI: 10.3389/fimmu.2019.02315.
[63] ZHANG X X, SUN Y X, WANG N, et al. Immunomodulatory treatment strategies targeting B cells for heart failure[J]. Front Pharmacol, 2022, 13: 854592. DOI: 10.3389/fphar.2022.854592.
[64] MA X L, LIN Q Y, WANG L, et al. Rituximab prevents and reverses cardiac remodeling by depressing B cell function in mice[J]. Biomed Pharmacother, 2019, 114: 108804. DOI: 10.1016/j.biopha.2019.108804.